Septerna, Inc. Depreciation and Amortization Expense
Septerna, Inc. (SEPN) reported Depreciation and Amortization Expense of $848.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DepreciationAndAmortization · last filed 2026-08-10
- Septerna, Inc. depreciation, depletion and amortization, nonproduction for the quarter ending 2026-06-30 was $427.00K, a 5.43% increase year-over-year.
- Septerna, Inc. depreciation, depletion and amortization, nonproduction for the quarter ending 2026-03-31 was $421.00K, a 6.05% increase year-over-year.
- Septerna, Inc. depreciation, depletion and amortization, nonproduction for the quarter ending 2025-12-31 was $401.00K, a 3.35% increase year-over-year.
- Septerna, Inc. depreciation, depletion and amortization, nonproduction for the quarter ending 2025-09-30 was $401.00K, a 10.16% increase year-over-year.
- Septerna, Inc. depreciation, depletion and amortization, nonproduction for fiscal 2025 was $1.60M, a 14.49% increase from fiscal 2024.
- Septerna, Inc. depreciation, depletion and amortization, nonproduction for fiscal 2024 was $1.40M, a 65.21% increase from fiscal 2023.
- Septerna, Inc. depreciation, depletion and amortization, nonproduction for fiscal 2023 was $848.00K.
| Period end | Depreciation, Depletion and Amortization, Nonproduction 3 month | Depreciation, Depletion and Amortization, Nonproduction 6 month | Depreciation, Depletion and Amortization, Nonproduction 9 month | Depreciation, Depletion and Amortization, Nonproduction 12 month |
|---|---|---|---|---|
| 2026-06-30 | $427.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $848.00K 10-Q · filed 2026-08-10 | $1.25M derived: sum of 3 quarters · filed 2026-08-10 | $1.65M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $421.00K 10-Q · filed 2026-05-11 | $822.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.22M derived: sum of 3 quarters · filed 2026-05-11 | $1.63M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $401.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $802.00K derived: sum of 2 quarters · filed 2026-03-09 | $1.21M derived: sum of 3 quarters · filed 2026-08-10 | $1.60M 10-K · filed 2026-03-09 |
| 2025-09-30 | $401.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $806.00K derived: sum of 2 quarters · filed 2026-08-10 | $1.20M 10-Q · filed 2025-11-10 | $1.59M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $405.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $802.00K 10-Q · filed 2026-08-10 | $1.19M derived: sum of 3 quarters · filed 2026-08-10 | $1.55M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $397.00K 10-Q · filed 2026-05-11 | $785.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.15M derived: sum of 3 quarters · filed 2026-05-11 | $1.48M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $388.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $752.00K derived: sum of 2 quarters · filed 2026-03-09 | $1.08M derived: sum of 3 quarters · filed 2026-03-09 | $1.40M 10-K · filed 2026-03-09 |
| 2024-09-30 | $364.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $697.00K derived: sum of 2 quarters · filed 2025-11-10 | $1.01M 10-Q · filed 2025-11-10 | $1.26M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $333.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $649.00K 10-Q · filed 2025-08-11 | $892.00K derived: sum of 3 quarters · filed 2025-08-11 | |
| 2024-03-31 | $316.00K 10-Q · filed 2025-05-15 | $559.00K derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $243.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $848.00K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $605.00K 10-Q · filed 2024-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |